论文部分内容阅读
AIM:To evaluate the glycated hemoglobin(HbA_(1c))determination methods and to determine fructosamine inpatients with chronic hepatitis,compensated cirrhosis andin patients with chronic hepatitis treated with ribavirin.METHODS:HbA_(1c) values were determined in 15 patientswith compensated liver cirrhosis and in 20 patients withchronic hepatitis using the ion-exchange high performanceliquid chromatography and the immunoassay methods.Fructosamine was determined using nitroblue tetrazolium.RESULTS:Forty percent of patients with liver cirrhosis hadHbA_(1c) results below the non-diabetic reference range by atleast one HbA_(1c)method,while fructosamine results wereeither within the reference range or elevated.Twentypercent of patients with chronic hepatitis(hepatic fibrosis)had HbA_(1c)results below the non-diabetic reference rangeby at least one HbA_(1c)method.In patients with chronichepatitis treated with ribavirin,50% of HbA_(1c)results werebelow the non-diabetic reference using at least one of theHbA_(1c)methods.CONCLUSION:Only evaluated in context with all liverfunction parameters as well as a red blood count includingreticulocytes,HbA_(1c)results should be used in patients withadvanced liver disease.HbA_(1c)and fructosaminemeasurements should be used with caution when evaluatinglong-term glucose control in patients with hepatic cirrhosisor in patients with chronic hepatitis and dbavidn treatment.
AIM: To evaluate the glycated hemoglobin (HbA_ (1c)) determination methods and determine fructosamine inpatients with chronic hepatitis, compensated cirrhosis and in patients with chronic hepatitis treated with ribavirin. METHODS: HbA_ (1c) values were determined in 15 patients with compensated liver cirrhosis and in 20 patients with chronic hepatitis using the ion-exchange high performanceliquid chromatography and the immunoassay methods. Cructosamine was determined using nitroblue tetrazolium.RESULTS: Forty percent of patients with liver cirrhosis hadHbA_ (1c) results below the non-diabetic reference range by atleast one HbA_ (1c) method, while fructosamine results wereeither within the reference range or elevated. Twenty percent of patients with chronic hepatitis (hepatic fibrosis) had HbA_ (1c) results below the non-diabetic reference range by at least one HbA_ (1c) method. patients with chronic hepatitis with ribavirin, 50% of HbA_ (1c) results werebelow the non-diabetic reference using at least o ne of theHbA_ (1c) methods.CONCLUSION: Only evaluated in context with all liverfunction parameters as well as a red blood count includingreticulocytes, HbA_ (1c) results should be used in patients withadvanced liver disease. HbA_ (1c) and fructosaminemeasurements should be used with caution when evaluatinglong-term glucose control in patients with hepatic cirrhosisor in patients with chronic hepatitis and dbavidn treatment.